Research Papers:

Prognostic value of PD –L1 expression in patients with primary solid tumors

Xiao Xiang, Peng-Cheng Yu, Di Long, Xiao-Li Liao, Sen Zhang, Xue-Mei You, Jian-Hong Zhong and Le-Qun Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:5058-5072. https://doi.org/10.18632/oncotarget.23580

Metrics: PDF 1960 views  |   HTML 3554 views  |   ?  


Xiao Xiang1, Peng-Cheng Yu2, Di Long2, Xiao-Li Liao1, Sen Zhang2, Xue-Mei You1, Jian-Hong Zhong1 and Le-Qun Li1

1Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China

2Department of Colorectal Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

Correspondence to:

Le-Qun Li, email: [email protected]

Jian-Hong Zhong, email: [email protected], [email protected]

Keywords: primary solid tumors; programmed death ligand 1; overall survival; meta-analysis

Received: March 22, 2017     Accepted: December 13, 2017     Published: December 22, 2017


Programmed death-ligand 1 (PD-L1) is thought to play a critical role in immune escape by cancer, but whether PD-L1 expression can influence prognosis of patients with solid tumors is controversial. Therefore, we meta-analyzed available data on whether PD-L1 expression correlates with overall survival (OS) in such patients. PubMed, EMBASE and other databases were systematically searched for cohort or case-control studies examining the possible correlation between PD-L1 expression and OS of patients with solid tumors. OS was compared between patients positive or negative for PD-L1 expression using scatter plots, and subgroup analyses were performed based on tumor type and patient characteristics. Data from 59 studies involving 20,004 patients with solid tumors were meta-analyzed. The median percentage of tumors positive for PD-L1 was 30.1%. OS was significantly lower in PD-L1-positive patients than in PD-L1-negative patients at 1 year (P = 0.039), 3 years (P < 0.001) and 5 years (P < 0.001). The risk ratios of OS (and associated 95% confidence intervals) were 2.02 (1.56-2.60) at 1 year, 1.57 (1.34-1.83) at 3 years and 1.43 (1.24-1.64) at 5 years. Similar results were obtained in subgroup analyses based on patient ethnicity or tumor type. The available evidence suggests that PD-L1 expression negatively affects the prognosis of patients with solid tumors. PD-L1 might serve as an efficient prognostic indicator in solid tumor and may represent the important new therapeutic target.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23580